Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?

Citation
Giugliano D, Ceriello, A, De Nicola, L, et al. Diabetes Obes Metab 2020;22:149–57.